Allergan director acquires 3k+ shares — CNBC analyst calls company 'anti-bitcoin'

Written by Eric Oliver | January 02, 2018 | Print  |

Allergan Director Chris Bodline purchased 3,030 shares of company stock Dec. 7, The Ledger Gazette reports.

Here's four insights into Allergan:

1. Mr. Bodine purchased the shares at an average cost of $164.77 per share, for a total of $499,253.

2. Allergan has a 52-week high of $256.80 and a 52-week low of $160.07.

3. The company hit $163.58 Jan. 1.

4. CNBC analyst Jim Cramer criticized the company's stock saying it "can't catch a break." Mr. Cramer said Allergan is facing "endless competition," with no immediate path to create separation," the Kaplan Herald reports.

Mr. Cramer compared Allergan to the booming cryptocurrency Bitcoin saying the drug maker is the "anti-bitcoin," concerning gained value. Mr. Cramer believes Allergan's stock has no immediate pathway to achieve increased value.

More articles on gastroenterology: 
Drs. William Maher, Scott Altschuler & more: 3 GI physicians making headlines
Emmy partners with The Endoscopy Center of New York, Westside GI Center — 3 insights
14 statistics on pain management net revenue per case, volume at ASCs

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.